Okamura K, Hamazaki Y, Yajima A, Noda K
Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
Biomed Pharmacother. 1989;43(3):177-81. doi: 10.1016/0753-3322(89)90212-6.
In order to prolong the survival of patients with cervical cancer, adjuvant immunotherapy was undertaken in Japan. The result of two randomized controlled studies using biological response modifiers such as OK-432 or sizofiran are described. The three-year recurrence-free rates of 221 patients in the OK-432 group and 161 patients in the control group were 71.9% and 58.6%, respectively. The intergroup difference was statistically significant. Of all the patients with Stage II or III cancer, time to recurrence and survival rate in 99 patients in the sizofiran group were significantly longer than in 96 patients in the control, evaluated at 5 years. Based on the results of the 2 randomized controlled studies, we conclude that adjuvant immunotherapy is very useful for prolonging the survival of patients with cervical cancer.
为延长宫颈癌患者的生存期，日本开展了辅助免疫治疗。本文描述了两项使用OK-432或云芝多糖K等生物反应调节剂的随机对照研究结果。OK-432组的221例患者和对照组的161例患者的三年无复发生存率分别为71.9%和58.6%。组间差异具有统计学意义。在所有II期或III期癌症患者中，云芝多糖K组的99例患者与对照组的96例患者相比，5年评估时的复发时间和生存率显著更长。基于这两项随机对照研究的结果，我们得出结论，辅助免疫治疗对于延长宫颈癌患者的生存期非常有用。
